HKSE - Delayed Quote HKD

WuXi AppTec Co., Ltd. (2359.HK)

185.400 -5.700 (-2.98%)

At close: October 30 at 4:08:06 PM GMT+8

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

PR Newswire 5d ago

603259.SS

2359.HK
-2.98%
How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated

GlobeNewswire 8d ago

2359.HK
-2.98%
Peptide Manufacturing Trends: How Oral Dosing Raises API Demand

GlobeNewswire 10d ago

603259.SS

2359.HK
-2.98%
WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

PR Newswire 12d ago

603259.SS

2359.HK
-2.98%
WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

PR Newswire 24d ago

603259.SS

2359.HK
-2.98%
Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions

GlobeNewswire 1mo ago

2359.HK
-2.98%
Oligonucleotide Drug Delivery Is Moving Beyond the Liver

GlobeNewswire 1mo ago

2359.HK
-2.98%
WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

PR Newswire 2mo ago

603259.SS

2359.HK
-2.98%
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

PR Newswire 2mo ago

2359.HK
-2.98%
603259.SS
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year

PR Newswire 3mo ago

603259.SS

2359.HK
-2.98%
Integrated Development Helps Targeted Protein Degraders Reach the Clinic

GlobeNewswire 3mo ago

2359.HK
-2.98%
Complex Small Molecules Are Changing Drug R&D

GlobeNewswire 4mo ago

2359.HK
-2.98%

U.S. markets closed

WuXi AppTec Co., Ltd. (2359.HK)

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

How Peptide Conjugate Developability Is Shaped Before a Candidate Is Nominated

Peptide Manufacturing Trends: How Oral Dosing Raises API Demand

WuXi AppTec Receives Frost & Sullivan's Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability

Long-Acting Oligonucleotide Development: Dosing, Yield and Stability Questions

Oligonucleotide Drug Delivery Is Moving Beyond the Liver

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year

Integrated Development Helps Targeted Protein Degraders Reach the Clinic

Complex Small Molecules Are Changing Drug R&D